Thanks..link wasn't on the earnings presentation page when I had looked..
Seems like KTE-X19 is separated out vs axi-cel trials, so I guess they will name it something different than Yescarta when launched?
Only difference is its manufactured differently?
3 preclinical CART trials using different mechanisms
Allogenic CART cd19 vs DLBCL
Anti CLL-1 vs AML
Dual antigen vs DLBCL
So looks like they focusing on DLBCL target again even though Yescarta does that.
Likely since they have the most data in those indications to make the best upgraded drugs.
Nice safe way to make your first allogenic product by making an allogenic Yescarta.